NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...
Diagnostic test based on urinary tumor markers hold promise for earlier or prompt detection of bladder cancer in patients ...
Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it ...
Hosted on MSN
Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study
We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Relmada Therapeutics, Inc. is one of them. Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotechnology ...
Aura Biosciences (NASDAQ:AURA) highlighted progress across its ocular oncology pipeline and provided updates on a parallel ...
Zacks Investment Research on MSN
JNJ's bladder cancer therapy meets key goal in early-stage study
Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical ...
RAANANA, Israel (Reuters) - Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced ...
Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...
Detailed price information for Theralase Techs Inc (TLTFF) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results